Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cefiderocol - Shionogi

Next Previous
X
Search
Drug Profile

Cefiderocol - Shionogi

Alternative Names: Cefiderocol-sulfate-tosylate; FETCROJA; Fetcroja; Fetroga; FETROJA; Fetroja; GSK 2696266; RSC 649266; S-649266

Latest Information Update: 24 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi
  • Developer Shionogi; The University of Queensland
  • Class Antibacterials; Cephalosporins
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gram-negative infections; Urinary tract infections
  • Registered Nosocomial pneumonia; Ventilator associated pneumonia
  • Phase II Intra-abdominal infections; Sepsis

Most Recent Events

  • 17 Sep 2024 Shionogi completes a phase II trial in Gram-negative infections (In adolescents, In children, In infants) in USA, Australia, Greece, Lithuania, Mexico, Panama, Philippines, Spain, and Ukraine (NCT04215991) (EudraCT2019-002121-30)
  • 17 Sep 2024 Shionogi completes a phase II trial in Nosocomial pneumonia (In children, In infants, In adolescents) in USA, Australia, Greece, Lithuania, Mexico, Panama, Philippines, Spain, and Ukraine (NCT04215991) (EudraCT2019-002121-30)
  • 17 Sep 2024 Shionogi completes a phase II trial in Urinary tract infections (Complicated, In adolescents, In children, In infants) in USA, Australia, Greece, Lithuania, Mexico, Panama, Philippines, Spain, and Ukraine (NCT04215991) (EudraCT2019-002121-30)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top